Kura Oncology : Investor Event Presentation

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

EHA Investor Event - June 12, 2023

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation also contains statistical and clinical data obtained from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation.

2

Today's Agenda

Topic	Speaker
Welcome / Opening Remarks	Troy Wilson, Ph.D., J.D., President and Chief Executive Officer
Introduction of KOMET-001 Investigators	Stephen Dale, M.D., Chief Medical Officer
Opportunity in AML / KOMET-001 Trial Design	Ghayas Issa, M.D., MD Anderson Cancer Center
Presentation of KOMET-001 Phase 1b Data	Amir Fathi, M.D., Massachusetts General Hospital
Ziftomenib Clinical Development Path	Mollie Leoni, M.D., Senior Vice President, Clinical Development
Q & A session	All
Closing Remarks	Troy Wilson, Ph.D., J.D., President and Chief Executive Officer

3

Ziftomenib Represents a Transformational Therapy for AML

1

2

3

4

Highly

Differentiated

Meaningful

Durability

Potential to

Sequence

Earlier

Expanding Beyond NPM1 and KMT2A

Ziftomenib is uniquely positioned within and outside of menin class with ideal monotherapy properties translating into superior early clinical activity

Rationale for ziftomenib as a highly durable and well-tolerated maintenance therapy to transform acute leukemias into a chronic disease

Clinical evidence building to demonstrate role of ziftomenib sequencing first ahead of IDH1/2i and FLT3i

Demonstrated clinical activity in other AML subtypes beyond NPM1-m and KMT2A-r to broaden patient potential

4

KOMET-001 Investigators

Ghayas Issa, M.D.		Amir Fathi, M.D.
• Hematology & Oncology, Departments of	• Program Director, Center for Leukemia,
Leukemia and Genomic Medicine, MD	Massachusetts General Hospital Cancer
Anderson Cancer Center	Center
• Assistant Professor, Department of	• Associate Professor of Medicine, Harvard
Leukemia, The University of Texas MD	Medical School
Anderson Cancer Center

5